Search clinical trials for: Atopic Dermatitis, JAK1 inhibitor

Total 68987 results

Pfizer

Completed

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis (JADE TEEN)

Atopic Dermatitis

Spain, United States, Taiwan, Germany, China, Hungary, Australia, Czechia, Japan, Latvia, Poland, United Kingdom, Mexico, Italy
Karyopharm Therapeutics Inc

Active, not recruiting

A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis

Myelofibrosis

Spain, China, Poland, United States, France, Greece, Italy
Incyte Corporation

Withdrawn

A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis
Philipps University Marburg Medical Center

Completed

Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS (RuXoCoil)

COVID | ARDS, Human

Germany
Emma Guttman
Pfizer

Completed

Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia

Cicatricial Alopecia

United States
Yale University
Pfizer

Recruiting

Janus Kinase Inhibition in Sarcoidosis

Sarcoidosis

United States
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

Severe Aplastic Anemia | Single Lineage Cytopenias, T-LGL | Hypoplastic MDS

United States
University of Utah
Karyopharm Therapeutics Inc

Active, not recruiting

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Incyte Corporation

Completed

Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects

Acute Graft-versus-host Disease

Japan
Pfizer

Terminated

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Plaque Psoriasis

United States, Canada
Incyte Corporation

Terminated

Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

Bronchiolitis Obliterans Syndrome

United States, Belgium, Canada
Jinnah Hospital

Completed

Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

Pakistan
Incyte Corporation

Completed

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Priovant Therapeutics, Inc.

Recruiting

A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis (VALOR)

Dermatomyositis

United States, Belgium, Germany, Hungary, Israel, Italy, Netherlands, Portugal, Korea, Republic of, Bulgaria, Poland, Romania, Czechia, Taiwan, Chile, Mexico, Turkey, Serbia, Spain, United Kingdom, Canada
Eli Lilly and Company

Completed

Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy

Arthritis, Rheumatoid

Japan
Incyte Corporation

Terminated

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

Acute Graft-versus-host Disease

United States, Spain, France, Italy, United Kingdom, Germany
National Cancer Institute (NCI)

Active, not recruiting

Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Chronic Graft vs Host Disease | Chronic Graft-Versus-Host Disease

United States
The Lymphoma Academic Research Organisation
Novartis

Completed

A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma (HIJAK)

Hodgkin's Lymphoma

France, Belgium
Sichuan University

Unknown

Ruxolitinib Plus LVP in Patients With R/R ETP-ALL

Acute T Cell Leukemia
Pfizer

Completed

A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers

Phase 1

Belgium
The Children's Hospital of Zhejiang University...
First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Qilu Hospital... and other collaborators

Recruiting

Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis

Cytokine Storm | Hemophagocytic Lymphohistiocytoses

China
Eli Lilly and Company
Incyte Corporation

Completed

A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

Arthritis, Rheumatoid

Hungary, Romania, United States, Czechia, Croatia, Poland, Ukraine, Mexico, India
AstraZeneca

Terminated

A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

Gastric Cancer | Advanced Solid Malignancies | Solid Tumour | Child-Pugh A to B7 Advanced Hepatocellular Carcinoma | EGFR and/or ROS Mutant NSCLC | Lung Metastasis Carcinoma

Korea, Republic of
Pfizer

Completed

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

Healthy Females

United States
Incyte Corporation

Completed

A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lymphoma

United States
Novartis Pharmaceuticals

Completed

Long-term Study of Ciclosporin for Atopic Dermatitis

Severe Atopic Dermatitis
Novartis Pharmaceuticals

Completed

Verification Study of Ciclosporin for Atopic Dermatitis

Severe Atopic Dermatitis
AbbVie

Not yet recruiting

A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis (Sleep Up)

Sleep Disturbance | Atopic Dermatitis
AbbVie

Recruiting

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic Dermatitis

United States
Instituto de Investigación Hospital Universitario...

Recruiting

Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models

Atopic Dermatitis

Spain
Pfizer

Not yet recruiting

Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry) (ATTRACT)

Skin Diseases | Immune System Diseases | Dermatitis | Eczema | Dermatitis, Atopic | Janus Kinase Inhibitors
Innovaderm Research Inc.

Not yet recruiting

Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

Chronic Hand Eczema

Canada
Incyte Corporation

Recruiting

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population (OPERA-1)

Pregnancy Related | Atopic Dermatitis

United States
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (AQUA)

Dermatitis Atopic

Chile, United Kingdom, United States, Canada, Turkey, Israel, Korea, Republic of
medac GmbH

Not yet recruiting

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

Moderate to Severe Atopic Dermatitis
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis (TRuE-AD4)

Atopic Dermatitis

Germany, Poland, United States, Spain, United Kingdom, Italy, Belgium, Canada, Netherlands, Australia, Bulgaria, France, Switzerland, Hungary, Korea, Republic of
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE)

Dermatitis Atopic

Japan, Chile, Canada, Argentina, United States, Turkey, China
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1)

Dermatitis Atopic

Israel, Chile, Australia, United States, Canada, Korea, Republic of, Taiwan, China
MEDA PHARMA SPA, a Viatris company

Not yet recruiting

Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis. (Elidel-SEA)

Mild to Moderate Atopic Dermatitis
Societa Italiana di Dermatologia Medica, Chirurgica...

Recruiting

Real-world Experience on the Use of Upadacitinib in the Treatment of Moderate-severe Adult Atopic Dermatitis (ERUDA) (ERUDA)

Atopic Dermatitis

Italy
Medical University of Vienna

Recruiting

The Effect of Desflurane Versus Sevoflurane Versus Propofol on Postoperative Delirium (RAPID-II)

Postoperative Delirium | Postoperative Cognitive Dysfunction | Major Noncardiac Surgery

Austria
Innovaderm Research Inc.

Recruiting

Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects With Atopic Dermatitis

Atopic Dermatitis

Canada
King's College London
Guy's and St Thomas' NHS Foundation Trust

Recruiting

Mind and Skin - the Neurocutaneous Axis in Atopic Eczema

Atopic Dermatitis

United Kingdom
HK inno.N Corporation

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

Mild to Moderate Atopic Dermatitis
Pfizer
PPD

Recruiting

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

Atopic Dermatitis

United States
Instituto de Investigación Hospital Universitario...

Recruiting

Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response (DermAtOmics)

Atopic Dermatitis

Spain
Pfizer

Recruiting

A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis. (ADAIR)

Eczema | Atopic Dermatitis

France
Fundación Academia Española de Dermatología

Recruiting

Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy (BIOBADATOP)

Dermatitis, Atopic

Spain
Innovaderm Research Inc.

Recruiting

Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

Atopic Dermatitis

Canada, United States
Sanofi

Recruiting

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials (RIVER-AD)

Dermatitis Atopic

Canada, United States, Australia, Bulgaria, Czechia, Germany, Hungary, Japan, Poland, Spain, Taiwan, United Kingdom

3

Subscribe